TROKENDI XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TROKENDI XR (TROKENDI XR).
Selective inhibitor of neuronal and glial voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive firing. Also blocks L-type calcium channels and enhances GABA-A receptor activity.
| Metabolism | Hepatic metabolism via glucuronidation (UGT1A1, UGT1A3, UGT1A4, UGT2B7, UGT2B15) and CYP3A4 isoenzymes. Excreted primarily in urine as glucuronide conjugates and unchanged drug. Autoinduction of metabolism occurs with chronic use. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 70% of the dose; the remainder is eliminated as metabolites in urine and feces. Biliary excretion is minimal. |
| Half-life | 15-20 hours in healthy adults; allows twice-daily dosing. Steady state reached in 5-7 days. |
| Protein binding | Topiramate is 15-41% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.6-0.8 L/kg; indicates extensive distribution into total body water. |
| Bioavailability | Oral bioavailability is approximately 80%. |
| Onset of Action | Oral: Peak plasma concentration at 3-12 hours; clinical effect typically within 24-72 hours. |
| Duration of Action | Approximately 12 hours due to twice-daily dosing; sustained release provides stable plasma levels over 24 hours. |
| Molecular Weight | 339.3 |
Initial dose: 50 mg orally twice daily; titrate weekly by 50 mg/day to a target maintenance dose of 200-400 mg/day in two divided doses; maximum 400 mg/day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 30-49 mL/min: maximum 200 mg/day; GFR 15-29 mL/min: maximum 150 mg/day; GFR <15 mL/min or hemodialysis: maximum 100 mg/day with supplemental dose of 100 mg after 4-hour hemodialysis. |
| Liver impairment | Child-Pugh Class A: reduce dose by 20%; Class B: reduce by 50%; Class C: avoid use. |
| Pediatric use | Not approved for pediatric patients; safety and efficacy not established. |
| Geriatric use | Initiate at lower end of dosing range due to age-related renal impairment; consider monitoring renal function and titrate slowly. |
| 1st trimester | Topiramate, the active ingredient, is associated with increased risk of oral clefts (cleft lip/palate) when used during first trimester. Data from North American Antiepileptic Drug Pregnancy Registry indicates prevalence of oral clefts approximately 1.2% vs 0.4% in unexposed. Use only if benefit outweighs risk. |
| 2nd trimester | Continued exposure associated with risk of fetal growth restriction and low birth weight. Monitor fetal growth with ultrasound. Consider dose adjustment to lowest effective dose. |
| 3rd trimester | May cause maternal metabolic acidosis and fetal effects including hyperchloremic metabolic acidosis in neonate. Consider monitoring acid-base status. Neonatal withdrawal or jitteriness possible. |
Clinical note
Comprehensive clinical and safety monograph for TROKENDI XR (TROKENDI XR).
| Placental transfer | Topiramate readily crosses the placenta. Cord blood concentrations approximate maternal plasma concentrations (ratio 0.83-1.0). Fetal exposure is significant. |
| Breastfeeding |
■ FDA Black Box Warning
Explicit FDA boxed warning: Increased risk of suicidal thoughts or behavior in patients taking antiepileptic drugs; monitor for emergence or worsening of depression, suicidal thoughts/behavior, or unusual changes in mood or behavior.
| Serious Effects |
Hypersensitivity to topiramate or any component of the formulationInitiation or titration in patients with acute or chronic metabolic acidosisPatients with a history of nephrolithiasis (relative; caution)
| Precautions | Suicidal behavior and ideation; aseptic meningitis; hypersensitivity reactions (DRUG-induced hypersensitivity syndrome, Stevens-Johnson syndrome); hepatotoxicity; pancreatitis; blood dyscrasias (agranulocytosis, thrombocytopenia); teratogenicity (fetal anticonvulsant syndrome); worsening of seizures; dizziness and somnolence; hyponatremia. |
| Food/Dietary | Avoid high-fat meals as they may increase the rate and extent of topiramate absorption (Cmax increases by 50%, AUC increases by 15%). Grapefruit and grapefruit juice may increase topiramate levels; avoid concurrent use. Maintain adequate hydration to reduce risk of nephrolithiasis; avoid excessive intake of vitamin C and acidic foods that may acidify urine. |
Loading safety data…
| Topiramate is excreted into human milk. Milk/plasma ratio is approximately 0.86. Infant serum levels may reach up to 10-20% of maternal therapeutic levels. Monitor infant for diarrhea, somnolence, and adequate weight gain. Use with caution in breastfeeding women, especially if infant has renal impairment. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | Trokendi XR (topiramate) is classified as Pregnancy Category D. There is evidence of human fetal risk based on data from pregnancy registries. First trimester exposure increases the risk of oral clefts (cleft lip with or without cleft palate) approximately 3- to 5-fold compared to unexposed infants. Second and third trimester exposure is associated with an increased risk of low birth weight and small for gestational age. Topiramate may also cause metabolic acidosis during pregnancy, which can affect the fetus. |
| Fetal Monitoring | Monitor maternal serum topiramate levels throughout pregnancy as clearance may increase. Assess maternal acid-base status with serum bicarbonate levels due to risk of metabolic acidosis. Perform fetal ultrasound to evaluate for oral clefts after first trimester exposure. Monitor fetal growth in the second and third trimesters. Neonates should be monitored for withdrawal symptoms, metabolic acidosis, and low birth weight. |
| Fertility Effects | Topiramate may cause reproductive dysfunction in women, including anovulation, menstrual irregularities, and decreased fertility. It can also decrease serum estradiol levels and alter hormonal contraceptive efficacy. In men, no significant effects on fertility have been reported. |
| Clinical Pearls | TROKENDI XR is an extended-release formulation of topiramate for epilepsy and migraine prophylaxis. Titrate slowly to minimize cognitive side effects. Monitor for metabolic acidosis, especially in patients with renal impairment or on ketogenic diet. May cause oligohidrosis and hyperthermia, particularly in pediatric patients. Contraception counseling is essential due to potential oral contraceptive failure and teratogenicity (Pregnancy Category D). |
| Patient Advice | Swallow tablets whole; do not crush, chew, or split. · Take with food if GI upset occurs; avoid high-fat meals which may affect absorption. · Drink plenty of fluids to prevent kidney stones. · Seek immediate medical attention for sudden eye pain or blurred vision (possible acute myopia/secondary angle closure glaucoma). · Report symptoms of metabolic acidosis: fatigue, tachypnea, arrhythmias. · Use reliable contraception; topiramate can reduce efficacy of hormonal contraceptives. · Avoid alcohol and CNS depressants as they may exacerbate sedation. · Do not stop abruptly; taper to avoid rebound seizures. · May cause cognitive slowing, word-finding difficulties; caution with driving or operating machinery. |